|Bid||9.05 x 4000|
|Ask||9.25 x 4000|
|Day's Range||8.71 - 9.14|
|52 Week Range||7.25 - 17.35|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Wall Street was cheering for Teva on Monday after the Israeli pharmaceutical giant received FDA approval finally for its migraine drug Ajovy. Shares of ...
NEW YORK, Aug. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allegiance ...
NEW YORK, Aug. 07, 2018-- TG Therapeutics, Inc. today announced its financial results for the second quarter ended June 30, 2018 and recent company developments. Michael S. Weiss, the Company's Executive ...
TG Therapeutics, Inc. (TGTX) today announced that target enrollment in the ULTIMATE I and II Phase 3 trials has been achieved. ULTIMATE I and II are two independent Phase 3 clinical trials evaluating the safety and efficacy of ublituximab (TG-1101), the Company’s glycoengineered anti-CD20 monoclonal antibody, as compared to teriflunomide, in patients with relapsing forms of Multiple Sclerosis (RMS). While target enrollment has been reached, in order to provide an opportunity for patients already identified to participate, enrollment is expected to continue until mid-September.
Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will host the call. An audio recording of the conference call will also be available for replay on the Company’s website, for a period of 30 days after the call. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.
LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on TRVN sign up now at www.wallstequities.com/registration. On Monday, July 09, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green.
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TGTX sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), United Therapeutics Corp. (NASDAQ: UTHR), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA).